NASDAQ:ARYD ARYA Sciences Acquisition Corp IV (ARYD) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free ARYD Stock Alerts $11.42 -0.03 (-0.26%) (As of 05/30/2024 ET) Add Compare Share Share Today's Range$11.42▼$11.4250-Day Range$11.23▼$11.4452-Week Range$10.45▼$11.45Volume104 shsAverage Volume39,790 shsMarket Capitalization$86.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Ad American AlternativeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About ARYA Sciences Acquisition Corp IV Stock (NASDAQ:ARYD)Arya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.Read More ARYD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARYD Stock News HeadlinesFebruary 14, 2024 | msn.comAdagio Medical to go public in $113M deal with SPAC ARYA SciencesFebruary 14, 2024 | finance.yahoo.comAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesFebruary 14, 2024 | prnewswire.comAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesApril 7, 2023 | marketwatch.com8-K: ARYA Sciences Acquisition Corp IVFebruary 24, 2022 | benzinga.comARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus' Gene Therapy Business Due to Market ConditionsNovember 30, 2021 | finance.yahoo.comMoore Kuehn Encourages KOR, DISCA, FTSI, and ARYD Investors to Contact Law FirmNovember 9, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of EJF, HTPA, ARYD, and ADER MergersOctober 6, 2021 | finance.yahoo.comMoore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law FirmOctober 1, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ARYA Sciences Acquisition Corp. IV MergerSeptember 30, 2021 | entrepreneur.comAmcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYASeptember 30, 2021 | msn.comAmicus Therapeutics Stock Rises; Sells Unit Stake in SPAC DealSeptember 30, 2021 | finance.yahoo.comAmicus stock is up 5%, the day after announcing plans to sell its gene therapy businessSeptember 29, 2021 | finance.yahoo.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD)September 29, 2021 | feeds.benzinga.comPerceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy BusinessSeptember 29, 2021 | apnews.comAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a ...September 29, 2021 | finance.yahoo.comAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”See More Headlines Company Calendar Today5/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:ARYD CUSIPN/A CIK1838821 Webwww.perceptivelife.com Phone212-284-2300FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.83% Return on Assets-6.48% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book-5.92Miscellaneous Outstanding Shares7,540,000Free Float3,508,000Market Cap$86.11 million OptionableNot Optionable Beta-0.01 Key ExecutivesMr. Adam Leo Stone (Age 44)CEO & Director Mr. Michael Seth Altman CFA (Age 42)CFO & Director Mr. Konstantin Poukalov (Age 40)Chief Business Officer Key CompetitorsCascadia AcquisitionNASDAQ:CCAIAlpha Healthcare Acquisition Corp. IIINASDAQ:ALPAARYA Sciences Acquisition Corp VNASDAQ:ARYECodere Online LuxembourgNASDAQ:CDROInflection Point Acquisition Corp. IINASDAQ:IPXXView All CompetitorsInstitutional OwnershipShaolin Capital Management LLCSold 150,000 shares on 5/17/2024Ownership: 1.588%Berkley W R CorpBought 130,598 shares on 5/16/2024Ownership: 4.237%Affinity Asset Advisors LLCBought 133,500 shares on 5/15/2024Ownership: 1.771%K2 Principal Fund L.P.Bought 39,248 shares on 5/14/2024Ownership: 0.521%Periscope Capital Inc.Sold 225,000 shares on 5/13/2024Ownership: 0.995%View All Institutional Transactions ARYD Stock Analysis - Frequently Asked Questions How have ARYD shares performed in 2024? ARYA Sciences Acquisition Corp IV's stock was trading at $10.90 on January 1st, 2024. Since then, ARYD stock has increased by 4.7% and is now trading at $11.4150. View the best growth stocks for 2024 here. Are investors shorting ARYA Sciences Acquisition Corp IV? ARYA Sciences Acquisition Corp IV saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 100 shares, a drop of 50.0% from the April 30th total of 200 shares. Based on an average daily trading volume, of 14,400 shares, the days-to-cover ratio is presently 0.0 days. View ARYA Sciences Acquisition Corp IV's Short Interest. When did ARYA Sciences Acquisition Corp IV IPO? ARYA Sciences Acquisition Corp IV (ARYD) raised $130 million in an IPO on Friday, February 26th 2021. The company issued 13,000,000 shares at $10.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO. Who are ARYA Sciences Acquisition Corp IV's major shareholders? ARYA Sciences Acquisition Corp IV's stock is owned by a number of retail and institutional investors. Top institutional investors include Berkley W R Corp (4.24%), Mizuho Securities USA LLC (3.21%), Affinity Asset Advisors LLC (1.77%), Shaolin Capital Management LLC (1.59%), Periscope Capital Inc. (0.99%) and K2 Principal Fund L.P. (0.52%). How do I buy shares of ARYA Sciences Acquisition Corp IV? Shares of ARYD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARYD) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyGet out of dollars—get into America’s new money insteadStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist My Default Watchlist Adding ARYA Sciences Acquisition Corp IV You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
